103 related articles for article (PubMed ID: 24083612)
21. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
Haro I; Gómara MJ; Galatola R; Domènech O; Prat J; Girona V; Busquets MA
Biochim Biophys Acta; 2011 Jun; 1808(6):1567-73. PubMed ID: 21377446
[TBL] [Abstract][Full Text] [Related]
22. Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART.
Björkman P; Flamholc L; Molnegren V; Marshall A; Güner N; Widell A
AIDS; 2007 Jul; 21(12):1641-3. PubMed ID: 17630561
[TBL] [Abstract][Full Text] [Related]
23. GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality.
Björkman P; Flamholc L; Nauclér A; Molnegren V; Wallmark E; Widell A
AIDS; 2004 Apr; 18(6):877-86. PubMed ID: 15060435
[TBL] [Abstract][Full Text] [Related]
24. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
[TBL] [Abstract][Full Text] [Related]
25. Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.
Souza IE; Allen JB; Xiang J; Klinzman D; Diaz R; Zhang S; Chaloner K; Zdunek D; Hess G; Williams CF; Benning L; Stapleton JT
J Clin Microbiol; 2006 Sep; 44(9):3105-13. PubMed ID: 16954234
[TBL] [Abstract][Full Text] [Related]
26. A novel peptide shows excellent anti-HIV-1 potency as a gp41 fusion inhibitor.
Liu W; An X; Wang J; Zhang X; Tan J; Zhou Z; Zeng Y
Bioorg Med Chem Lett; 2018 Mar; 28(5):910-914. PubMed ID: 29433929
[TBL] [Abstract][Full Text] [Related]
27. Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.
Sánchez-Martín MJ; Busquets MA; Girona V; Haro I; Alsina MA; Pujol M
Biochim Biophys Acta; 2011 Sep; 1808(9):2178-88. PubMed ID: 21672514
[TBL] [Abstract][Full Text] [Related]
28. Beneficial effect of GB virus C co-infection in Human Immunodeficiency Virus type 1-infected individuals.
Hattori J; Okumura N; Yamazaki Y; Uchiyama M; Hamaguchi M; Nishiyama Y; Kaneda T
Microbiol Immunol; 2007; 51(2):193-200. PubMed ID: 17310087
[TBL] [Abstract][Full Text] [Related]
29. Characterization of GBV-C infection in HIV-1 infected patients.
Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of GB virus type C in urban Americans infected with human immunodeficiency virus type 1.
Smith SM; Donio MJ; Singh M; Fallon JP; Jitendranath L; Chkrebtii N; Slim J; Finkel D; Perez G
Retrovirology; 2005 May; 2():38. PubMed ID: 15927079
[TBL] [Abstract][Full Text] [Related]
31. GB virus C genotype determination in GB virus-C/HIV co-infected individuals.
Muerhoff AS; Tillmann HL; Manns MP; Dawson GJ; Desai SM
J Med Virol; 2003 May; 70(1):141-9. PubMed ID: 12629656
[TBL] [Abstract][Full Text] [Related]
32. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C.
Jung S; Eichenmüller M; Donhauser N; Neipel F; Engel AM; Hess G; Fleckenstein B; Reil H
AIDS; 2007 Mar; 21(5):645-7. PubMed ID: 17314528
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i+3, respectively, derived from HIV-1 gp41 C-peptide.
Lee MK; Kim HK; Lee TY; Hahm KS; Kim KL
Exp Mol Med; 2006 Feb; 38(1):18-26. PubMed ID: 16520549
[TBL] [Abstract][Full Text] [Related]
34. Impact of GB virus C viraemia on clinical outcome in HIV-1-infected patients: a 20-year follow-up study.
Ernst D; Greer M; Akmatova R; Pischke S; Wedemeyer H; Heiken H; Tillmann HL; Schmidt RE; Stoll M
HIV Med; 2014 Apr; 15(4):245-50. PubMed ID: 24118889
[TBL] [Abstract][Full Text] [Related]
35. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 and GBV-C co-infection in Venezuela.
Rodríguez AK; Garzaro DJ; Loureiro CL; Gutiérrez CR; Ameli G; Jaspe RC; Porto L; Monsalve F; Pozada Á; Vázquez L; Quiñones-Mateu ME; Pujol FH; Rangel HR
J Infect Dev Ctries; 2014 Jul; 8(7):863-8. PubMed ID: 25022296
[TBL] [Abstract][Full Text] [Related]
37. Design of antiviral stapled peptides containing a biphenyl cross-linker.
Muppidi A; Zhang H; Curreli F; Li N; Debnath AK; Lin Q
Bioorg Med Chem Lett; 2014 Apr; 24(7):1748-51. PubMed ID: 24613163
[TBL] [Abstract][Full Text] [Related]
38. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
[TBL] [Abstract][Full Text] [Related]
39. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients.
Rodriguez B; Woolley I; Lederman MM; Zdunek D; Hess G; Valdez H
J Infect Dis; 2003 Feb; 187(3):504-7. PubMed ID: 12552436
[TBL] [Abstract][Full Text] [Related]
40. GB virus C infection in children with perinatal human immunodeficiency virus infection.
Schuval S; Lindsey JC; Stapleton JT; Van Dyke RB; Palumbo P; Mofenson LM; Oleske JM; Cervia J; Kovacs A; Dankner WN; Smith E; Nowak B; Ciupak G; Webb N; Eagle M; Smith D; Hennessey R; Goodman-Kerkau M; Klinzman D; Hess G; Zdunek D; Levin MJ;
Pediatr Infect Dis J; 2005 May; 24(5):417-22. PubMed ID: 15876940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
